Myriad Genetics (MYGN) Share-based Compensation (2009 - 2026)

Myriad Genetics (MYGN) has reported Share-based Compensation for 18 consecutive years, with $6.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Share-based Compensation fell 31.58% year-over-year to $6.5 million; the TTM figure through Mar 2026 stood at $32.2 million (down 56.49% YoY), while the FY2025 annual figure was $35.2 million, down 29.32% from the prior year.
• Share-based Compensation grew to $6.5 million in Q1 2026 per MYGN's latest filing, from $2.8 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $37.6 million in Q4 2024 and bottomed at -$21.5 million in Q4 2023.
• Historically, Share-based Compensation has averaged $9.1 million across 5 years, with a median of $10.1 million in 2022.
• Annual changes were most pronounced in 2022 — Share-based Compensation jumped 10300.0% — and 2023, when it slumped 1533.33%.
• Myriad Genetics' Share-based Compensation stood at $1.5 million in 2022, then plunged by 1533.33% to -$21.5 million in 2023, then jumped by 274.88% to $37.6 million in 2024, then plunged by 92.55% to $2.8 million in 2025, then surged by 132.14% to $6.5 million in 2026.
• Business Quant data shows MYGN's Share-based Compensation at $6.5 million in Q1 2026, $2.8 million in Q4 2025, and $12.2 million in Q3 2025.